Improved injection site reactions after switching from adalimumab reference to adalimumab biosimilar LBAL for ulcerative colitis: A case report.

MLA

Yudai Hirakawa, et al. “Improved Injection Site Reactions after Switching from Adalimumab Reference to Adalimumab Biosimilar LBAL for Ulcerative Colitis: A Case Report.” Medicine, vol. 103, no. 44, Nov. 2024, pp. 1–4. EBSCOhost, https://doi.org/10.1097/MD.0000000000040400.

APA

Yudai Hirakawa, Toshihiko Kakiuchi, Masato Yoshiura, & Nao Kikkawa. (2024). Improved injection site reactions after switching from adalimumab reference to adalimumab biosimilar LBAL for ulcerative colitis: A case report. Medicine, 103(44), 1–4. https://doi.org/10.1097/MD.0000000000040400

Chicago

Yudai Hirakawa, Toshihiko Kakiuchi, Masato Yoshiura, and Nao Kikkawa. 2024. “Improved Injection Site Reactions after Switching from Adalimumab Reference to Adalimumab Biosimilar LBAL for Ulcerative Colitis: A Case Report.” Medicine 103 (44): 1–4. doi:10.1097/MD.0000000000040400.